Table 1.
Baseline demographics and clinical and treatment characteristics of ADHD subjects
| Age (years±SD) | 9.9±2.2 |
| Sex (male/female) | 7/3 |
| Race (% Japanese) | 100 |
| Height (cm±SD) | 140.5±15.5 |
| Weight (kg±SD) | 38.6±17.3 |
| Tipepidine hibenzate dosage (mg/kg/day ±SD) | 1.288±0.349 |
| ADHD subtypes (combined/inattentive/hyperimpulsive) | 7/3/0 |
| WISC-III/IV full IQ score±SD | 87.4±13.3 |
| Comorbidity (n) | 4 |
| Learning disorder | 2 |
| Tic disorder | 1 |
| Learning disorder and tic disorder | 1 |
| Pharmacotherapy (n) | 7 |
| Methylphenidate | 2 |
| Atomoxetine | 1 |
| Aripiprazole | 1 |
| Methylphenidate and atomoxetine | 1 |
| Atomoxetine and aripiprazole | 1 |
| Methylphenidate and risperidone | 1 |
| Naïve | 3 |
Note: Reported values are means ± standard deviation (n=10) or percentages.
Abbreviations: ADHD, attention deficit/hyperactivity disorder; WISC-III/IV, Wechsler Intelligence Scale for Children III/IV; SD, standard deviation; IQ, intelligence quotient.